Arachidonoyl Serotonin - CAS:187947-37-1

您当前的位置：

Arachidonoyl Serotonin (Synonyms:N-Arachidonoylserotonin; AA-5-HT)

目录号 : KCM12214 CAS No. : 187947-37-1 纯度 : ≥98%

Data Sheet 产品使用指南

Arachidonoyl serotonin is an inhibitor of fatty acid amide hydrolase (FAAH), the enzyme responsible for inactivation of anandamide and other endogenous cannabinoids. It inhibits the FAAH activity isolated from mouse neuroblastoma cells with an IC value of 12 µM. Both the K and the V of the enzyme are affected, indicating the Arachidonoyl serotonin is a very tight binding, competitive inhibitor of FAAH. Arachidonoyl serotonin does not inhibit cPLA and is essentially devoid of cannabimimetic activity.

规格	价格	是否有货	数量
5mg		In-stock
10mg		In-stock
50mg		In-stock

加入购物车大包装询价

Other Forms of Rapamycin:

AM374 In-stock
Arachidonoyl Serotonin In-stock
Carprofen In-stock
Biochanin A In-stock

KKL Med 的所有产品和服务仅用于科学研究，不能被用于人体，兽医，我们也不向个人提供产品和服务。

生物活性

Arachidonoyl Serotonin is a dual FAAH inhibitor and TRPV1 antagonist. Arachidonoyl Serotonin blocks Anandamide hydrolysis, increases brain Anandamide levels, and promotes CB1 receptor signaling in the dorsal hippocampus. Arachidonoyl Serotonin normalizes HPA axis dysregulation, reduces plasma corticosterone levels, and induces anxiolytic-like effects in mice. Arachidonoyl Serotonin reverses behavioral despair, inhibits contextual fear memory retrieval, and produces dose-dependent antinociceptive effects in rodents. Arachidonoyl Serotonin inhibits intestinal motility. Arachidonoyl Serotonin can be used to study stress-related disorders, traumatic memory and related psychiatric disorders, pain, and intestinal motility disorders.

IC₅₀&Target

CB1

hTRPV1

体外研究

Arachidonoyl Serotonin (30 min) inhibited FAAH in rat meninges with an IC50 of 8 μM.
Arachidonoyl Serotonin (2 h) is a potent antagonist of hTRPV1 in HEK293 cells, with an IC50 of 0.27 μM.
Arachidonoyl Serotonin (50 μM) does not inhibit MAGL even at concentrations up to 50 μM in cell-free homogenates.

体内研究

N-arachidonoylseletonin (2.5-5 mg/kg; intraperitoneal injection; Three doses were administered 24 hours, 5 hours, and 1 hour before FST testing or sacrifice to reverse stress-induced behavioral despair and restore HPA axis dysregulation to normal. The most significant behavioral effect was observed in rats at a dose of 5 mg/kg.
N-Arachidonoylseletonin (0.1-1 mg/kg; intraperitoneal injection; 30 minutes before the test, inhibit the retrieval of situational fear memory in mice.
N-Arachidonoylseletonin (1-20 mg/kg; intraperitoneal injection; Single time; 30 minutes before labeling, significant inhibitory effects were observed on intestinal motility in mice at doses of 10 mg/kg and above, with the effect partially mediated by CB1 receptors .
N-Arachidonoylseletonin (15 mg/kg; intraperitoneal injection; Single dose significantly inhibited intestinal peristalsis in CB1 receptor deficient mice, although this effect was partially dependent on the CB1 receptor (wild-type inhibited 42% vs. mutant mice inhibited 22%).

Animal Model:	Wistar rats (male, 220-240 g, 4 h restraint stress model)
Dosage:	2.5 mg/kg; 5 mg/kg
Administration:	i.p.; three times at 24 h, 5 h, and 1 h prior to FST test or sacrifice
Result:	Reversed behavioral despair at 5 mg/kg, significantly decreasing immobility time and increasing climbing time. Completely reversed stress-induced elevation of plasma corticosterone levels at 5 mg/kg. Significantly increased BDNF mRNA and protein levels in the hippocampus at 2.5 mg/kg. Increased BDNF mRNA levels and showed a trend for increase in protein levels at 5 mg/kg. Significantly elevated anandamide (AEA) levels in the medial PFC at 2.5 mg/kg. Did not significantly alter BDNF levels in non-stressed animals except for a decrease in mRNA expression at 5 mg/kg. Caused a significant elevation of corticosterone levels in non-stressed rats at 2.5 mg/kg.

Animal Model:	Swiss mice (male, 25-30 g)
Dosage:	0.1, 0.3, and 1.0 mg/kg (i.p.); 0.125, 0.25, and 0.5 nmol (intra-hippocampal)
Administration:	i.p. (30 min before test); intra-hippocampal (10 min before test)
Result:	Decreased freezing responses at all i.p. doses (0.1, 0.3, 1 mg/kg) during the expression of contextual fear memory. Did not affect freezing when administered before conditioning at 0.3 mg/kg. Decreased freezing at intra-hippocampal doses of 0.125 and 0.25 nmol, but the 0.5 nmol dose was ineffective. Did not interfere with basal motor activity in the open field test.

Animal Model:	ICR mice (Male, 20-22 g)
Dosage:	1, 2.5, 5, 10, 15, 20 mg/kg
Administration:	i.p.; single dose; 30 min before marker
Result:	Inhibited intestinal motility in a dose-dependent manner, with significant effects starting at 10 mg/kg. Was significantly reduced by rimonabant (0.1 mg/kg) when combined with a 15 mg/kg dose. Increased the inhibitory effect of anandamide and PEA at 5 mg/kg. Increased small intestine levels of anandamide (1.85 pmol/mg lipid at 10 mg/kg vs. control 1.08 pmol/mg lipid) and 2-AG (2.30 nmol/mg lipid at 10 mg/kg vs. control 1.23 nmol/mg lipid) starting from 10 mg/kg. Increased PEA levels at 15 mg/kg (9.36 pmol/mg lipid vs. control 6.60 pmol/mg lipid).

Animal Model:	CB1 receptor-deficient mice and wild-type littermates (Female, 19-22 g)
Dosage:	15 mg/kg
Administration:	i.p.; single dose; 30 min before marker
Result:	Significantly reduced intestinal motility in CB1 receptor-deficient mice. Induced a larger reduction in motility in wild-type mice (42% inhibition) compared to CB1 receptor-deficient mice (22% inhibition).

Animal Model:	FAAH-deficient mice (Female, 19-22 g)
Dosage:	15 mg/kg
Administration:	i.p.; single dose; 30 min before marker
Result:	Significantly reduced intestinal motility in FAAH-deficient mice.

分子式

C₃₀H₄₂N₂O₂

分子量

462.67

CAS号

187947-37-1

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

-80°C

纯度： ≥98%

Data Sheet

产品使用指南

Ortar G, et al. New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain. J Med Chem. 2007 Dec 27;50(26):6554-69.

Capasso R, et al. Fatty acid amide hydrolase controls mouse intestinal motility in vivo. Gastroenterology. 2005 Sep;129(3):941-51.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量

浓度

体积

分子量*

重置计算

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2

浓度

体积

浓度

体积

重置计算

动物实验计算换算器

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系客服为您提供正确的澄清溶液配方）

% DMSO

% Tween 80

% ddH₂O

% DMSO

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系客服）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

配置后的溶液总体积：

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

Other Forms of Rapamycin:

KKL 顾客使用本产品发表的 0 篇科研文献

The molarity calculator equation

The dilution calculator equation

动物实验计算换算器